Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Olumacostat glasaretil 是乙酰辅酶A 羧化酶的有效抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 538 | 现货 | ||
2 mg | ¥ 692 | 现货 | ||
5 mg | ¥ 995 | 现货 | ||
10 mg | ¥ 1,490 | 现货 | ||
25 mg | ¥ 2,570 | 现货 | ||
50 mg | ¥ 3,830 | 现货 | ||
100 mg | ¥ 5,490 | 现货 | ||
200 mg | ¥ 7,680 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,050 | 现货 |
产品描述 | Olumacostat glasaretil is a small molecule inhibitor of acetyl coenzyme A carboxylase (ACC). It has been used in trials studying the treatment of Acne Vulgaris. |
体外活性 | Acetyl coenzyme A carboxylase controls the first, rate-limiting step in fatty acid biosynthesis. Olumacostat glasaretil inhibits de novo lipid synthesis in primary and transformed human sebocytes. Olumacostat glasaretil reduces fatty acid synthesis to at or below baseline levels at 3 μM. 14C-acetate incorporation levels are 85%-90% lower for SEB-1 cultures treated with olumacostat glasaretil at 20 μM compared to control samples. At 3 μM, olumacostat glasaretil reduces sebocyte triacylglycerol, cholesteryl/wax ester, diacylglycerol, cholesterol and phospholipid levels from control values on average by approximately 86%, 57%, 51%, 39% and 37%, respectively[1]. |
体内活性 | Olumacostat glasaretil is a pro-drug of the ACC inhibitor 5-(tetradecyloxy)-2-furoic acid (TOFA) and is designed to enhance delivery in vivo. Topical application of olumacostat glasaretil but not TOFA significantly reduces hamster ear sebaceous gland size. HPLC analyses of hamster ear extracts shows that olumacostat glasaretil treatment increases ACC levels and the ratio of acetyl-CoA to free CoA in tested animals which suggests increased fatty acid oxidation. These changes are consistent with ACC inhibition. Matrix-assisted laser desorption/ionization (MALDI) imaging reveals that OG applied onto Yorkshire pig ears accumulates in sebaceous glands relative to the surrounding dermis[1]. At week 12, OG treatment shows greater reductions from baseline in inflammatory lesions and noninflammatory lesions, and more patients with greater than or equal to 2-grade improvement in investigator global assessment score than vehicle[2]. |
细胞实验 | Primary human sebocytes are grown to confluence in 96-well plates in sebocyte growth medium and stimulated with 1 μM human insulin and 1 μM liver X receptor (LXR) agonist T0901317 in the presence of increasing concentrations of TOFA or olumacostat glasaretil in culture medium containing 0.1% DMSO. After 24 hours, stimulation/treatment medium is removed and test articles are reapplied in labeling medium containing [14C]-acetate. Following an additional 16 hours, cells are harvested using trypsin/EDTA. Lipid extracts are prepared and the amount of [14C]-acetate incorporation is determined by liquid scintillation as a measure of de novo fatty acid synthesis[1]. |
分子量 | 481.62 |
分子式 | C26H43NO7 |
CAS No. | 1261491-89-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 0.1 mg/mL (insoluble)
DMSO: 125 mg/mL (259.54 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0763 mL | 10.3816 mL | 20.7633 mL | 51.9081 mL |
5 mM | 0.4153 mL | 2.0763 mL | 4.1527 mL | 10.3816 mL | |
10 mM | 0.2076 mL | 1.0382 mL | 2.0763 mL | 5.1908 mL | |
20 mM | 0.1038 mL | 0.5191 mL | 1.0382 mL | 2.5954 mL | |
50 mM | 0.0415 mL | 0.2076 mL | 0.4153 mL | 1.0382 mL | |
100 mM | 0.0208 mL | 0.1038 mL | 0.2076 mL | 0.5191 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Olumacostat Glasaretil 1261491-89-7 Metabolism Acetyl-CoA Carboxylase inhibit ACC, Acetyl Coenzyme A Carboxylase Inhibitor inhibitor